The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women

Antiviral Therapy

Volumn 16, Issue 2, 2011, Pages 149-156

  Sevinsky, Heather ^a   Eley, Timothy ^a   Persson, Anna ^a   Garner, Dennis ^a   Yones, Cynthia ^a   Nettles, Richard ^a   Krantz, Kathryn ^a   Bertz, Richard ^a   Zhang, Jenny ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; LEVONORGESTREL; NORELGESTROMIN; PROGESTERONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG INDUCED HEADACHE; DRUG SAFETY; ELECTROCARDIOGRAM; FEMALE; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; METRORRHAGIA; MULTICENTER STUDY; NORMAL HUMAN; OPEN STUDY; PHARMACODYNAMICS; PLASMA CONCENTRATION-TIME CURVE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; BENZOXAZINES; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SYNTHETIC; DRUG INTERACTIONS; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; NORGESTREL; REVERSE TRANSCRIPTASE INHIBITORS; YOUNG ADULT;

EID: 79953192509     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1725     Document Type: Article

References (29)

1. Heikinheimo O, Lahteenmaki P. Contraception and HIV infection in women. Hum Reprod Update 2009; 15:165-176.
2. Fakoya A, Lamba H, Mackie N, et al. British HIV Association, BASHH and FSRH guidelines for the management of the sexual and reproductive health of people living with HIV infection 2008. HIV Med 2008; 9:681-720.
3. Hammer SM, Eron JJ, Jr., Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. December 4, 2009. Department of Health and Human Services (Accessed 10 December 2009.) Available from http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
5. Sustiva (efavirenz). US prescribing information 2009. Bristol-Myers Squibb, Princeton, NJ, USA.
6. Sustiva (efavirenz). Summary of product characteristics 2009. Bristol-Myers Squibb, Uxbridge, UK.
7. Van Vliet HA, Grimes DA, Helmerhorst FM, Schulz KF. Biphasic versus triphasic oral contraceptives for contraception. Cochrane Database Syst Rev 2006; 3:CD003283.
8. Maitra N, Kulier R, Bloemenkamp KW, Helmerhorst FM, Gulmezoglu AM. Progestogens in combined oral contraceptives for contraception. Cochrane Database Syst Rev 2004; 3:CD004861.
9. El Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care 2008; 13:123-132. (Pubitemid 352000659)
10. Isentress (raltegravir). US prescribing information 2009. Merck & Co., Inc, Whitehouse Station, NJ, USA.
11. Kent UM, Mills DE, Rajnarayanan RV, Alworth WL, Hollenberg PF. Effect of 17-alpha-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J Pharmacol Exp Ther 2002; 300:549-558.
12. Hammond GL, Abrams LS, Creasy GW, Natarajan J, Allen JG, Siiteri PK. Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception 2003; 67:93-99.
13. Palovaara S, Pelkonen O, Uusitalo J, Lundgren S, Laine K. Inhibition of cytochrome P450 2B6 activity by hormone replacement therapy and oral contraceptive as measured by bupropion hydroxylation. Clin Pharmacol Ther 2003; 74:326-333. (Pubitemid 37222853)
14. Palovaara S, Kivisto KT, Tapanainen P, Manninen P, Neuvonen PJ, Laine K. Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1′-hydroxylation. Br J Clin Pharmacol 2000; 50:333-337.
15. Belle DJ, Callaghan JT, Gorski JC, et al. The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity. Br J Clin Pharmacol 2002; 53:67-74. (Pubitemid 34117741)
16. Balogh A, Gessinger S, Svarovsky U, et al. Can oral contraceptive steroids influence the elimination of nifedipine and its primary pryidine metabolite in humans? Eur J Clin Pharmacol 1998; 54:729-734.
17. Kuhnz W, Blode H, Mahler M. Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women. Contraception 1994; 49:255-263. (Pubitemid 124009888)
18. Ortho Tri-Cyclen LO (norgestimate/ethinyl estradiol). US prescribing information 2008. Ortho-McNeil-Janssen Pharmaceuticals Inc., Raritan, NJ, USA.
19. Ortho Cyclen (norgestimate/ethinyl estradiol). US prescribing information 2008. Ortho-McNeil-Janssen Pharmaceuticals Inc., Raritan, NJ, USA.
20. US Food and Drug Administration. Guidance for industry: drug interaction studies - study design, data analysis, and implications for dosing and labeling. September 2006. (Accessed 4 December 2009.) Available from http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf
21. NIH Clinical Center. Progesterone historical reference ranges. National Institutes of Health. (Updated 20 March 2009. Accessed 4 December 2009.) Available from http://cclnprod.cc.nih.gov/dlm/testguide.nsf/Index/CB26894E1EB 28DEF85256BA5005B000E?OpenDocument
22. London RS, Chapdelaine A, Upmalis D, Olson W, Smith J. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet Gynecol Scand Suppl 1992; 156:9-14.
23. Weiss J, Herzog M, Konig S, Storch CH, Ketabi-Kiyanvash N, Haefeli WE. Induction of multiple drug transporters by efavirenz. J Pharmacol Sci 2009; 109:242-250.
24. Josephson F, Bertilsson L, Bottiger Y, et al. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. Eur J Clin Pharmacol 2008; 64:775-781.
25. Chu JH, Gange SJ, Anastos K, et al. Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy. Am J Epidemiol 2005; 161:881-890. (Pubitemid 40577843)
26. Cohn SE, Park JG, Watts DH, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther 2007; 81:222-227. (Pubitemid 46174819)
27. Nanda K, Amaral E, Hays M, Viscola MA, Mehta N, Bahamondes L. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertil Steril 2008; 90:965-971.
28. Watts DH, Park JG, Cohn SE, et al. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. Contraception 2008; 77:84-90.
29. Matiluko AA, Soundararjan L, Hogston P. Early contraceptive failure of Implanon in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz. J Fam Plann Reprod Health Care 2007; 33:277-278. (Pubitemid 47597636)